ArticleOncology letters2026
Circular RNA hsa_circ_0006168: A potential biomarker for the diagnosis and prognosis of prostate cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The limited specificity of prostate-specific antigen for prostate cancer (PCa) necessitates novel, non-invasive biomarkers. The present study aimed to investigate the expression of the circular (circ)RNA hsa_circ_0006168 in PCa and its association with clinical parameters, and to evaluate its potential as a diagnostic and prognostic biomarker for PCa. Serum samples were collected from patients with PCa, benign prostatic hyperplasia (BPH) and healthy controls. Reverse transcription-quantitative PCR was used to measure the expression level of hsa_circ_0006168 in the sera. The association between the expression of hsa_circ_0006168 and several clinicopathological parameters was subsequently analyzed, and univariate and multivariate Cox regression analyses were performed to identify factors affecting prognosis. The expression level of hsa_circ_0006168 in the sera of patients with PCa was revealed to be significantly higher compared with that in the patients with BPH and the healthy controls. The area under the receiver operating characteristic curve was 0.773. The clinicopathological parameter analysis revealed that a high expression level of hsa_circ_0006168 was positively associated with the Gleason score, consistent with circRNA sequencing data. Cox regression analysis revealed that tumor-node-metastasis staging was an independent risk factor affecting prognosis. Furthermore, the expression level of hsa_circ_0006168, the Gleason score and bone metastasis were identified as significant risk factors according to the univariate Cox regression analysis; however, no significant factors were identified in the multivariate Cox regression analysis. In conclusion, serum hsa_circ_0006168 may be a promising biomarker for the early diagnosis and prognosis evaluation of PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.